{
  "ticker": "ASND",
  "company_name": "Ascendis Pharma A/S",
  "success": true,
  "trials": [
    {
      "nct_id": "NCT05598320",
      "title": "A Clinical Trial to Evaluate Efficacy and Safety of TransCon CNP Compared With Placebo in Children With Achondroplasia",
      "status": "COMPLETED",
      "phase": "PHASE2, PHASE3",
      "condition": "Achondroplasia",
      "start_date": "2023-03-03",
      "completion_date": "2025-08-13",
      "enrollment": 0,
      "sponsor": "Ascendis Pharma Growth Disorders A/S"
    },
    {
      "nct_id": "NCT06433557",
      "title": "A Phase 2 Clinical Trial to Evaluate Efficacy, Safety, and Tolerability of Navepegritide in Combination With Lonapegsomatropin in Children With Achondroplasia",
      "status": "ACTIVE_NOT_RECRUITING",
      "phase": "PHASE2",
      "condition": "Achondroplasia",
      "start_date": "2024-07-26",
      "completion_date": "2027-09",
      "enrollment": 0,
      "sponsor": "Ascendis Pharma Growth Disorders A/S"
    },
    {
      "nct_id": "NCT07345494",
      "title": "A Global Pregnancy Registry to Assess Maternal, Fetal, and Infant Outcomes Following Exposure to YORVIPATH\u00ae (Palopegteriparatide) During Pregnancy and Breastfeeding",
      "status": "NOT_YET_RECRUITING",
      "phase": "",
      "condition": "Hypoparathyroidism",
      "start_date": "2026-01",
      "completion_date": "2036-01",
      "enrollment": 0,
      "sponsor": "Ascendis Pharma A/S"
    },
    {
      "nct_id": "NCT07221851",
      "title": "Trial Investigating the Efficacy and Safety of Weekly Lonapegsomatropin Compared to Daily Somatropin in Children and Adolescents With Short Stature or Growth Failure Due to Growth Hormone Sufficient Disorders",
      "status": "RECRUITING",
      "phase": "PHASE3",
      "condition": "Turner Syndrome, Short Stature Homeobox Gene Mutation, Idiopathic Short Stature, Small for Gestational Age at Delivery",
      "start_date": "2025-12-12",
      "completion_date": "2029-03",
      "enrollment": 0,
      "sponsor": "Ascendis Pharma A/S"
    },
    {
      "nct_id": "NCT04799054",
      "title": "A Study of TransCon TLR7/8 Agonist With or Without Pembrolizumab in Patients With Advanced or Metastatic Solid Tumors",
      "status": "TERMINATED",
      "phase": "PHASE1, PHASE2",
      "condition": "Advanced Solid Tumor, Locally Advanced Solid Tumor, Metastatic Solid Tumor, Head and Neck Squamous Cell Carcinoma HNSCC, HPV-associated Cancers, Neoadjuvant Melanoma, Neoadjuvant Cutaneous Squamous Cell Carcinoma (cSCC)",
      "start_date": "2021-03-18",
      "completion_date": "2025-12-02",
      "enrollment": 0,
      "sponsor": "Ascendis Pharma Oncology Division A/S"
    },
    {
      "nct_id": "NCT04009291",
      "title": "A Trial Investigating the Safety, Tolerability and Efficacy of TransCon PTH in Adults With Hypoparathyroidism",
      "status": "COMPLETED",
      "phase": "PHASE2",
      "condition": "Hypoparathyroidism, Endocrine System Diseases, Parathyroid Diseases",
      "start_date": "2019-08-27",
      "completion_date": "2025-04-17",
      "enrollment": 0,
      "sponsor": "Ascendis Pharma A/S"
    },
    {
      "nct_id": "NCT05654701",
      "title": "Expanded Access Program of Palopegteriparatide in Patients With Hypoparathyroidism",
      "status": "APPROVED_FOR_MARKETING",
      "phase": "",
      "condition": "Hypoparathyroidism",
      "start_date": "",
      "completion_date": "",
      "enrollment": 0,
      "sponsor": "Ascendis Pharma Bone Diseases A/S"
    },
    {
      "nct_id": "NCT07264634",
      "title": "A Study to Assess the Amount of Palopegteriparatide in Breast Milk of Lactating Females Requiring YORVIPATH\u00ae (Palopegteriparatide)",
      "status": "NOT_YET_RECRUITING",
      "phase": "",
      "condition": "Hypoparathyroidism",
      "start_date": "2026-01",
      "completion_date": "2028-01",
      "enrollment": 0,
      "sponsor": "Ascendis Pharma A/S"
    },
    {
      "nct_id": "NCT05690386",
      "title": "A Trial to Investigate Different Doses of Lonapegsomatropin Compared to Somatropin in Individuals With Turner Syndrome",
      "status": "ACTIVE_NOT_RECRUITING",
      "phase": "PHASE2",
      "condition": "Turner Syndrome",
      "start_date": "2023-02-15",
      "completion_date": "2027-12",
      "enrollment": 0,
      "sponsor": "Ascendis Pharma Endocrinology Division A/S"
    },
    {
      "nct_id": "NCT04701203",
      "title": "A Trial Investigating the Safety, Tolerability and Efficacy of TransCon PTH Administered Daily in Adults With Hypoparathyroidism",
      "status": "COMPLETED",
      "phase": "PHASE3",
      "condition": "Hypoparathyroidism, Endocrine System Diseases, Parathyroid Diseases",
      "start_date": "2021-02-16",
      "completion_date": "2025-01-21",
      "enrollment": 0,
      "sponsor": "Ascendis Pharma Bone Diseases A/S"
    }
  ],
  "summary": {
    "total_trials": 31,
    "by_phase": {
      "PHASE2, PHASE3": 2,
      "PHASE2": 10,
      "": 6,
      "PHASE3": 9,
      "PHASE1, PHASE2": 2,
      "PHASE1": 2
    },
    "by_status": {
      "COMPLETED": 13,
      "ACTIVE_NOT_RECRUITING": 2,
      "NOT_YET_RECRUITING": 3,
      "RECRUITING": 6,
      "TERMINATED": 3,
      "APPROVED_FOR_MARKETING": 1,
      "UNKNOWN": 2,
      "ENROLLING_BY_INVITATION": 1
    },
    "active_trials": 9,
    "completed_trials": 13,
    "conditions": [
      "Achondroplasia",
      "Adult Growth Hormone Deficiency",
      "Adult Growth Hormone Deficiency, Endocrine System Diseases, Hormone Deficiency",
      "Advanced Solid Tumor, Locally Advanced Solid Tumor, Metastatic Solid Tumor, Head and Neck Squamous Cell Carcinoma HNSCC, HPV-associated Cancers, Neoadjuvant Melanoma, Neoadjuvant Cutaneous Squamous Cell Carcinoma (cSCC)",
      "Advanced Solid Tumor, Locally Advanced Solid Tumor, Metastatic Solid Tumor, Platinum-resistant Ovarian Cancer, Post Anti-PD-1 Melanoma, 2L+ Cervical Cancer, Neoadjuvant Melanoma, Neoadjuvant Non-Small Cell Lung Cancer, Post Anti-PD-(L)1 Non-Small Cell Lung Cancer, Post Anti-PD-(L)1 Small Cell Lung Cancer, Third Line or Later (3L+) HER2+ Breast Cancer, Second or Third Line (2L/3L) Cervical Cancer, Third-line or Later (3L+) Platinum-resistant Ovarian Cancer (PROC)",
      "Growth Hormone Deficiency",
      "Growth Hormone Deficiency (GHD)",
      "Growth Hormone Deficiency, Endocrine System Diseases, Hormone Deficiency",
      "Growth Hormone Deficiency, Endocrine System Diseases, Hormones, Pituitary Diseases, Pituitary Disease, Anterior",
      "Growth Hormone Deficiency, Pediatric, Endocrine System Diseases, Hormone Deficiency, Pituitary Diseases",
      "Growth Hormone Deficiency, Pediatric, hGH (Human Growth Hormone), Endocrine System Diseases, Hormones, Pituitary Diseases",
      "Head and Neck Neoplasms",
      "Healthy",
      "Healthy Volunteers",
      "Hypoparathyroidism",
      "Hypoparathyroidism, Endocrine System Diseases, Parathyroid Diseases",
      "Turner Syndrome",
      "Turner Syndrome, Short Stature Homeobox Gene Mutation, Idiopathic Short Stature, Small for Gestational Age at Delivery"
    ],
    "lead_stage": "phase_3"
  },
  "provenance": {
    "source": "ClinicalTrials.gov API v2",
    "timestamp": "2026-01-29T12:16:39.458818",
    "search_query": "Ascendis Pharma A/S",
    "url": "https://clinicaltrials.gov/search?term=Ascendis+Pharma+A/S"
  }
}